Status:
COMPLETED
Safety, Tolerability and Pharmacokinetics of MK-0873 Following Patch Application in Healthy Participants and Psoriasis Participants (MK-0873-020)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will evaluate the incidence of erythema and other local cutaneous irritation after administration of MK-0873 by patch or cream formulation in healthy participants and participants with mild...
Eligibility Criteria
Inclusion
- Part I, II and III:
- Female participants of reproductive potential must test negative for pregnancy and agree to use two acceptable methods of birth control;
- In good general health;
- Nonsmoker;
- Part III only:
- Has diagnosis of plaque-type psoriasis, and has lesions covering at least 3% of total body surface area;
Exclusion
- Part I, II and III:
- Has a history of stroke, chronic seizures or major neurological disease;
- Has a history of cancer;
- Is a nursing mother;
- Part III only:
- Has nonplaque forms of psoriasis;
- Has current drug-induced psoriasis;
- Has received phototherapy, systemic medications/treatments, or used topical medication that could affect psoriasis;
- Has used any systemic immunosuppressants or biologics within the past 4 weeks.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01140061
Start Date
May 1 2010
End Date
March 1 2011
Last Update
February 8 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.